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INTRODUCTION
A. Background of Inflammatory Bowel Disease
1. Disease:
The child suffering from chronic inflammatory bowel disease (CIBD)
faces difficult problems in coping with a normal life style. For his
physician, chronic ulcerative colitis (CUC) and Crohn's disease (region
al enteritis, ileocolitis, and granulomatous colitis) pose real challen
ges due to their unpredictable chronic courses characterized by multiple
remissions, exacerbations, complications and variable responses to all
available therapy. This is true particularly since their etiologies re
main unknown and treatment is mostly empirical.
Clinically these diseases share many common features such as diar
rhea, rectal bleeding, abdominal pain, anorexia, weight loss, fever,
anemia, growth retardation and many extraintestinal manifestations such
as hepatic disease, arthralgias and arthritis, skin and mucous membrane
lesions (erythema nodosum, pyoderma gangrenosum, aphthous stomatitis,
erythema multiforme and Behcet's syndrome) and ocular complications (epi-
33
scleritis, iritis, conjunctivitis anduveitis). Likewise, from the
pathologist's view, the histologic findings in Crohn's disease and chron
ic ulcerative colitis may seem to overlap. At least 10% of cases with
CIBD remain unclassified in most reports in pathological literature.
The inflammatory process in Crohn's disease of the colon is classically
described as predominantly right sided, segmental and transmural, high-
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lighted by the presence of granulomas deeply situated in biopsy tissues
in up to 36% of the cases.
' ' In ulcerative colitis the disease
originates in the rectum and spreads proximally, but following steroid
therapy, and in a few unusual cases, the rectum might appear uninvolved.
Histologically, inflammation involves mostly the mucosa with extension
into other layers developing secondarily. Crypt abscesses (cryptitis
or crypt ulcers) have been identified as the initial characteristic
lesion of CUC, but they have also been found in other inflammatory dis-
34 35
eases of the gastrointestinal tract.
'
Radiologically, the distinction between ulcerative colitis and
Crohn's disease is more easily made in patients after the inflammatory
response has expressed itself considerably and extensive areas of the
colon are involved. Still, in 20-30% of the cases of ulcerative colitis
with involvement of the terminal ileum (backwash ileitis) a clear differ
entiation from granulomatous ileocolitis is not possible.
Because of all these similarities and overlaps, ulcerative colitis
and Crohn's disease are felt by some to represent the opposite extremes
of a single pathogenetic process. Indeed they are known to share common
epidemiologic characteristics (age, sex, and ethnic distribution) and
multiple occurrences of one or the other have been reported in the fami
lies of the patients. This hypothesis, which will be presented later
in this section, has not yet been completely clarified, and whether they




A comparable dilemma exists as to whether these diseases appear
33
to be the same in children and in adults. Both age groups seem to
share almost all the characteristics described in the foregoing, and
differ mostly in terms of percentages of more common symptoms. Rectal
bleeding is known to occur in only 20% of the children with ulcerative
colitis, but in 39% of the adults. The opposite occurs in Crohn's dis
ease, with rectal bleeding in 30% of the children, as compared to
6-13% in the adults.21
Both diseases often carry a poorer prognosis when their onset is
in childhood. This is especially true because of the potentially harm
ful effects of the diseases themselves and the iatrogenic effects on
the processes of growth and maturation which apply only to children.
Incidences of growth failure have been reported in 20-30% of children
with Crohn's disease who are less than 21 years of age, and in a some-
6,43
what smaller number of patients with ulcerative colitis. Another
major problem for children with CIBD is that their longer duration of
the disease increases the risk of developing carcinoma of the colon,
especially in those children with total colonic involvement. Of the
latter group, 50% who survive the disease for 25 years will develop
colonic carcinoma. A Mayo Clinic study of 396 children with ulcera
tive colitis, who were less than 14 years old at its onset, revealed
that 20% developed carcinoma after the first 10 years of disease, and
there was a 43% probability of developing carcinoma after 35 years of
the disease. Patients younger than 21 years at the onset of Crohn's
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disease also have an increased risk of carcinoma of the small bowel or
colon. Literature has led one to believe that the incidence of carci
noma in Crohn's disease is less, but some investigators believe that
a percentage of the patients previously classified as CUC actually had
n u t j. 33,55Crohn s disease.
It is unfortunate, therefore, that an increasing number of cases
of CIBD are recognized yearly in children and adolescents. New cases
52
of Crohn's disease in this age group are as, or more common than CUC.
Until recently, the overall incidence and prevalence of these diseases
in all age groups were reported as:
Incidence Prevalence
Chronic ulcerative colitis 3-6/100,000 44-99/100,000
Crohn's Disease .8-3.1/100,000 30-40/100,000
Presently the incidence seems to be rising, with 10-15% of all cases
33
reported as less than 15 years of age at time of onset.
The epidemiology of CIBD has been recognized as very similar in
children and adults. A white predominance has been noted, along with a
greater proportion of patients of Jewish background. Still, with all
these intriguing clinical correlations, the etiology of these diseases
remains an enigma to scientists and physicians in this field.
2. Etiology:
Diverse hypotheses have appeared in the literature in an attempt
to explain the underlying cause of these diseases. What makes a person
susceptible to CIBD? The most popular theories mentioned here are based
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on psychologic, microbiologic and immunologic findings,
1. Psychologic: After more than 40 years of implication, there
is no real evidence to support this concept. No single emotional or
psychological factor has been isolated in these patients and noted to
differ from any of those seen secondary to stress in any patients with
chronic, debilitating disease. Studies have also failed to reveal a
higher incidence of psychiatric disease in the patient group than in the
control population. Yet emotional factors and external pressures ap-
3
pear to influence directly the exacerbations in a number of the patients.
2. Microbiologic : Since CUC and Crohn's disease were initially
described, attempts to link infectious agents as causative factors of
these diseases were logical. Firstly, the histologic changes seen cer
tainly parallel findings typical of bacterial inflammation. Specific
analogies have been made between tuberculosis and sarcoid with Crohn's
disease and ulcerative colitis with bacillary dysentery. In more than
50 years, however, no single specific pathogen has been identified. Spe
cifically, Koch's postulates have not been satisfied, and most of the
organisms that have been linked (Diplostreptococcus, Shigella, Fusobac-
terium, E. coli, CMV, Mycobacterium) cause acute self-limited diseases
in man. Another argument against the microbiologic etiology is that if
bacteria played a major role, antibiotics should considerably alter the
disease patterns. Although Azulfidine is helpful, its beneficial ef




3. Immunologic; Strong evidence exists linking immune processes
in the development and continuity of bowel lesions found in chronic ul
cerative colitis and Crohn's disease. Both humoral and cell-mediated
mechanisms have been implicated by a vast amount of research and clinical
observations.
The characteristic histological lesion, i.e., the presence of
abundant lymphocytes, plasma cells, eosinophils, mast cells and phago
cytes, is typical of the setting in which possible Ag-Ab reactions
33
could take place. Results of multiple studies on antibody systems of
patients with CIBD have been non-specific. In patients with CUC, there
is still much controversy on whether the mean levels of serum immuno
globulins are elevated. Increased serum IgA has been reported, as well
as IgA deficiency. Serum antibodies against secretory IgA have been
33
found equally in normal controls and patients with CUC. Reports on
tissue immunoglobulins also vary. Gelzayd discovered in 1968, using im-
munofluorescent techniques, that the population density of IgA cells in
the lamina propria of the rectum of CUC patients was lower than in nor
mal rectal tissues, and that IgA was present in extracellular intersti-
33
tial mucosal sites unlike controls. Gebbers and Otto, by means of the
immunoperoxidase method, found that in biopsies of CUC patients, the ab
solute number of plasma cells increased with a marked increase of IgG
20
cells and a relative decrease of IgA cella. By tissue culture experi
ments, others proved that untreated CUC patients had increased production
of IgA and IgG over controls, and patients with bacterial enterocolitis.

7.
After immunotherapy, local Ig synthesis decreased to normal or subnor
mal levels corresponding with clinical improvement. Studies on IgE have
been contradictory. Also using immunofluorescent methods, IgE was noted
to be increased in the rectal mucosa of patients with proctitis over the
25
normal controls while others showed that the number of IgE cells
was not altered in CUC, but was markedly decreased in patients with
Crohn's.
More than 50 years ago, the cause of ulcerative colitis was first
believed to be an allergic reaction to cow's milk and other foods or
foreign antigens. Since then, multiple cases have been reported of milk
induced colitis but there is still no convincing evidence linking this
dietary intolerance with an allergic IgE mediated inflammatory gastroin
testinal disease.
For example, circulating antibodies to cow's milk proteins have
been shown in the sera of healthy controls as well as in patients with
Crohn's disease and ulcerative colitis. Whether the titer to a specific
milk antigen is actually more elevated in patients with CUC over Crohn's
and normals, is a matter of much controversy, since results seem to vary
33
with the different assays used. In a study of reagmic hypersensiti
vity in patients with CUC, intradermal tests against antibodies to dif
ferent cow's milk proteins, especially casein, were found to be positive
in CUC as well as in patients with Crohn's disease, hypolactasia, irri
table bowel syndrome and controls. No circulating IgE antibodies were
found specific for milk proteins, but an increased frequency of atopic
diseases was found in patients with CUC (15.7%) and Crohn's disease
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(13.3%) _ when compared with controls (.11 -2%). This study suggested that
the increased frequency of atopy In patients with CIBD reflects an in
creased susceptibility to the development of reaginic responses. How
ever, this mechanism does not apply to milk proteins since these speci-
30
fie reagins were not identified.
Circulating anti-colon antibodies have also been found in the
serum of patients with CUC and healthy relatives, as well as in patients
with chronic asthma and thyroid disease. This serum with anti-colon
antibodies (associated with IgG, IgM, IgA and secretory IgA types) is
not cytotoxic to human fetal colon cells. The titer of this anti-colon
antibody does not correlate with severity, duration, course and extent
of the disease. Its presence may, in fact, represent a secondary immuno
logic response to the existing bowel injury. On the other hand it could
also represent antibodies against heterogenetic antigens in bacteria
33
(E.coli 0.14) which are related to colonic antigens. Antibodies to
germ-free rat colon and to E.coli 0.14 have also been found in patients
with Crohn's colitis.
Cell-mediated immune responses have been studied extensively in pa
tients with CIBD. Results have been contradictory in more than one test
of immune competence including lymphocyte reactivity in vitro to non
specific mitogens (PHA) and skin tests for delayed hypersensitivity
(response to DNCB and -Mantoux) in both patients with CUC and Crohn's
disease. Bolton suggested in his study that reasons for conflicting re
ports were due to the use of a single test of immune competence and lack
of correlation with degree of disease activity and use of steroids.
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Therefore, he included all these variables and used 4 tests (blood peri
pheral lymphocyte levels, serum immunoglobulin levels, lymphocyte re
sponse to PHA, skin response to DNCB and Mantoux) , finally concluding
that there was no evidence of impairment of immune competence in patients
with Crohn's disease or ulcerative colitis.
Yet the issue of energy and CIBD has not been resolved. Crohn's
disease has been associated with sarcoidosis because of the presence of
non-epithelioid cell granulomas and energy. But experiments by Mitchell
and Rees, injecting cell-free extracts of diseased ileum and mesenteric
lymph nodes of Crohn's patients into footpads of normal and immunode-
ficient mice, revealed surprisingly that the granulomas were more common
in the normal mice. While some have produced small bowel granulomas by
inoculating Crohn's disease into diseased ileum, other investigators
have failed to reveal a single granuloma after working with diseased
bowels of 17 patients.
Peripheral lymphocytes from patients with CIBD have been shown to
be cytotoxic in vitro for autologous or allogenic colon epithelial cells.
Results of experiments by Stobo and Shorter suggest that these cytotoxic
cells do not belong to either T or B cells, but bear surface receptors
which combine with the Fc portion of Ig.
Finally, circulating antigen antibody complexes have been detected
in the sera of patients with Crohn's disease and CUC. The allocation of
these complexes in the bowel wall and other tissues could explain some
of the "serum sickness" manifestations associated with CIBD. Even the
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cytotoxicity of peripheral lymphocytes of patients with CIBD could be ex
plained by these antigen-antibody complexes, especially since it has been
previously shown that antibody target cell complexes can induce lympho
cyte cytotoxicity to specific antigens. Anti-colon antibodies which
cross react with heterogenetic antigens in many colonic bacteria could
possibly form these antigen-antibody complexes found in the sera of pa
tients with CIBD.
Because of the vast amount of data correlating the immune system
with CIBD, Shorter and his colleagues have postulated a working hypothe
sis in attempting to explain the possible role of immune mechanisms in
the etiology and pathogenesis of CIBD. Two basic assumptions of this
hypothesis are: (1) CUC and Crohn's disease are the extreme examples
of a single basic pathogenetic process, and (2) CIBD is the result of a
state of hypersensitivity to bacterial antigens normally present in the
gastro-intestinal tract.
Their first assumption is based on the vast amount of similar find
ings in patients with CUC and Crohn's disease
which have been previously
described. The second assumption rests on the theory that bacterial anti
gens are probably able to invade the lymphoid
tissue of the bowel wall
and draining lymph nodes before a mucosal block has been established
in
the young infant. This uptake of bacterial antigens could
be consider
ably increased by early exposure to cow's milk, particularly
in the non-
breast-fed infant. Subsequently, impairment of this mucosal block by in
sults such as infectious gastroenteritis, bacillary dysentery, amebic co-
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litis, ischemia and metabolic changes induced by stress via the autono
mic nervous system, could result in an altered state of hypersensitivity
in the bowel tissue.23,55,56
Some investigators, however, find this hypothesis inconvincing since
it leaves some questions unanswered. For example, why do not all indi
viduals primed and rechallenged develop CIBD? An attempted explanation
assumes that the individual's immune response to a specific antigen may
vary for allergic responses are not seen uniformly in all persons ex
posed to different allergens. A genetic predisposition could well be
involved, since an increase in familial incidence has been noted. Other
contributing factors in the gastrointestinal tract of these patients may
include a change in regional blood flow, differences in type and amount
of bile salts, and qualitative and quantitative changes in exposure to
enterobacterial antigens and bacterial endotoxins. Finally, after all
these requirements are met, enterobacterial antigens or related deter
minants in colonic epithelial cells and sensitized lymphocytes interact
resulting in the inflammatory changes seen in the bowel of patients with
CIBD.
The antigen-lymphocyte interaction is at the mucosal level in CUC
and superficial "backwash ileitis", while in Crohn's disease the same se
quence occurs in the submucosa, ultimately leading to a more productive
or granulomatous inflammation. Supporting this hypothesis is the fact
that the lesions in all cases of CUC and 90% of Crohn's are situated in
sites exposed to fecal flora. Observations have also been made in at
tempts to explain the post-surgical recurrences of Crohn's disease at
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anastomotic sites as secondary to an establishment of fecal type flora.
But still more research is needed to verify the exact nature of the an
tigens, target cells and sensitized lymphocytes involved in these hypo
thetic hypersensitivity reactions.
'
As mentioned previously, clinical observations have also linked
the immune system with CIBD. Some of these include an increased incidence
30
of personal and family histories of allergic disorders, occasional
multiplicity of connective tissue type of diseases in a patient with
CIBD such as arthritis, SLE, scleroderma and fibrosing pneumonitis, and
an increased familial incidence of Crohn's or CUC interchangeably.
Some laboratory findings in patients with ulcerative colitis also
suggest derangement in the immune mechanism, such as (1) Coomb's and
hemolytic anemia, and (2) hypergammaglobulinemia in the absence of liver
disease, and (3) hypoalbuminemia as seen in extensive bowel disease with
33
albumin loss into the lumen of the bowel and subsequent degradation.
3. Therapy of Chronic Inflammatory Bowel Disease:
In the same way, response to medical management of CIBD for more
than 20 years (specifically for ulcerative colitis) has also been con
sistent with the immunologic hypothesis. Although dosages and recom
mendations vary, this therapy generally consists of (1) oral adrenal
corticosteroids for control of active disease, (2) Azulfidine (Sulfa
salazine) for control of active disease and in prophylaxis, and (3) IV
21 33 52
ACTH or hydrocortisone during very severe attacks.
' '
Beneficial




immunosuppressive effects as well as other non-specific mechanisms.
Since the onset of the use of steroids in 1952 and Azulfidine in 1955,
the prognosis for ulcerative colitis has improved considerably. A sig
nificantly greater number of remissions have been achieved during the
first attack if corticosteroid therapy is instituted, and mortality and
morbidity rates following a first attack of ulcerative colitis have de
creased .
Unfortunately, usage of these drugs must often be discontinued
due to some of the side effects associated with them. Severe adverse re
actions to Azulfidine, for example, include agranulocytosis, leukopenia,
thrombocytopenia, hemolytic anemia related to G-6PD deficiency, and ur
ticaria. The frequency of these side effects varies 10-20% with each
study group. It has recently been shown that adverse effects are related
to serum sulfapyridine levels which, in turn, are affected by the dosage
33
and ability of the liner to acetylate. The use of oral adrenal cor
ticosteroids should be reserved for short-term courses to terminate moder
ate or severe acute attacks, since long-term steroid management of child
ren with CIBD has been shown to induce hypocalcemia, hypokalemia, symptoms
of adrenocorticism, and osteoporosis (which might lead to vertebral col
lapse and pathological compression fractures of the spine) , as
well as
retardation of bone growth and delayed sexual maturation often seen in
33,52
these patients.
The effects of steroids on growth failure have not yet been clearly
defined, since patients who usually show greater growth delay
are those
with more severe disease who require higher steroid dosage over longer
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periods of time. Reports of alterations in growth hormone levels have
been non-specific, and it has been demonstrated that exogenous adminis
tration of growth hormone does not improve growth. Other factors that
have been implicated include inadequate caloric intake secondary to
anorexia and abdominal symptoms, malabsorption, and malnutrition.
'
Interestingly, in a recent study by Whittington et al. of 16 adolescents
with Crohn's disease, suppression of disease activity was attempted
through continuous use of steroids in order to promote a normal growth
rate. Excellent symptomatic control and normal growth patterns were
achieved in 8 of the 16 patients with primarily ileal disease, and in 2
others with varying symptoms. Gryboski found a similar association in
which Crohn's patients with small bowel disease and no duodenal involve-
23
ment showed the best response to medical therapy.
Other modes of treatment include the use of Azathioprine (Imuran)
and other immunosuppressive agents in some patients with Crohn's disease
where response to Prednisone and Azulfidine has been less helpful. Al
though Imuran has appeared to be of some benefit in cases where entero-
cutaneous fistulae and severe perianal disease were reported to heal, its
toxic side effects (bone marrow depression and allergic toxicity) war
rant its use only in cases completely refractory to all other available
agents. Davidson reports that 3 out of 10 children who showed good
response had recurrence of symptoms approximately 3 to 6 months after
33
discontinuing Imuran therapy.
Supportive agents such as antidiarrheal medications
are sometimes
prescribed with caution on an individual basis. Opiates reduce pain,
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but they must be used very carefully in severe attacks since they may
inhibit bowel peristalsis, leading to toxic megacolon; anticholinergics
are helpful if used continuously; and Lomotil is considered by some to
be not helpful by some.
Antibiotics such as Tetracycline or Lincomycin have been recog
nized to be of occasional help, especially in patients with Crohn's dis
ease of the upper small bowel, or in those with evidence of abscess or
intestinal stasis, but they should never be used in conjunction with
23
Azulfidine.
Hyperalimentation has also been used recently to achieve complete
bowel rest, to reduce abdominal pain, and to treat malnutrition in an ef
fort to overcome growth failure in patients with anorexia, diarrhea and
weight loss. It has been most successful in alleviating symptoms in pa
tients recently diagnosed, rather than in those with acute reexacerba-
tions and profuse rectal bleeding, although it has still been helpful in
21
some of the more severe cases of Crohn's disease. Parenteral hyperali
mentation is also useful in preparing patients with CIBD for surgical
intervention. Surgery is indicated in extreme cases in which medical
therapy fails to terminate acute attacks or to prevent relapses, and
where the persistence of symptoms causes the child, who usually has
growth failure, to lead a very limited, abnormal life.
Total colectomy and ileostomy can be performed in one or two
21 22
stages in patients with CUC, where the terminal ileum is not involved.'
Foglia et al., summarizing their experiences with 47 patients, concluded
that of 23 who underwent surgery in one step, all achieved complete re-
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mission. Of the remaining 24 with subtotal colectomy, only 13 finally
achieved remission after a second operation where removal of the rectal
segment was completed. In this series, mortality associated with sur
gery was 0%, while morbidity was 25%. However, even though medical
success is achieved in those patients with total colectomy and ileostomy,
extensive psychological preparation must be given so that the patients
can cope with this irreversible procedure.
Indications for surgery differ for patients with Crohn's disease,
and the rate of recurrence after anastomotic procedures varies consider
ably. Homer and Grand presented data on 37 children and adolescents with
Crohn's disease who were operated for growth failure which showed that
catch-up growth was seen in only those operated before puberty and who
experienced no early recurrence. A recurrence rate of 30% was seen in
this series, approximately 2 years after the initial resection. It was




Recognizing the need for an alternative therapy for patients
with
CIBD who do not benefit from existing modes of treatment as outlined in
the foregoing, experimental trials of Cromolyn Sodium have
been made in
Great Britain in adult patients with ulcerative colitis and chronic proc-
. . 24,41
titis.
Cromolyn Sodium (Disodium Cromoglycate, DSCG,
"Intal" or "Aarane")




granulation with subsequent release of pharmacologic mediators such as
histamine, SRS-A, serotonin and bradykinin which follow certain antigen-
antibody reactions. In vitro experiments have revealed that Cromolyn
acts at a stage following antigen-antibody reactions, not necessarily re-
aginic mediated, but prior to the release of mediators of anaphylaxis.
'
Pharmacological studies have shown that this drug is relatively harmless.
Absorption through mucosal surfaces is reported to vary from less than
2% to 8% of the administered dose, and it is rapidly excreted unchanged
24 46
in the urine and bile.
'
Since Cromolyn remains unchanged during its
transit through the gastrointestinal tract, and has low levels of absorp
tion, it might well be effective in treating lesions of the gastrointes
tinal tract.
Because of its ability to block the normal sequence of events in
a Type I hypersensitivity reaction (immediate) , Cromolyn has proved very




vernal and allergic conjunctivitis, and aphthous stomatitis. Bene
ficial effects have also been observed in certain conditions of the
gastrointestinal tract such as gastrointestinal protein intolerance in
infants,
' '
food allergy in adults, sometimes associated with urti-
i j 32,46,68 , _, ,, ,




Therefore, on the basis that acute exacerbations in patients with
CIBD could also be mediated by Type I hypersensitivity reactions, studies
with Cromolyn were undertaken. Since an increase in the number of eo




tissue reactions such as in the bronchial mucosa of patients with ex
trinsic asthma, .as well as in the rectal mucosa of patients with ulcera
tive colitis, the use of Cromolyn in the latter condition could easily
be justified.
24,26,39,49,57
The promising results of the double-blind crossover trials per
formed in Great Britain prompted the Division of Pediatric Gastroenter
ology at Yale University Medical School to study the effects of oral
Cromolyn in patients whose disease was refractory to conventional therapy
with steroids or Azulfidine. The purpose of this thesis is to study the
clinical and histological effects of Cromolyn on mast cells in this group,
after establishing baseline criteria in patients with CIBD. If these pa
tients had any beneficial response to Cromolyn, was the drug acting in a
similar manner as it did in allergic asthma? Through the study of rectal
biopsies of these patients, both before and following Cromolyn therapy,
I was particularly interested in answers to the following: 1. Is the
actual number of mast cells increased in patients with ulcerative coli
tis, or with Crohn's disease? 2. Is there any change in the mast cell
population of the lamina propria of the rectum following Cromolyn therapy?
Is such a change consistent with the clinical response? 3. Can one pre
dict what type of patient, or what histologic characteristics of the bi
opsy are associated with good or poor response to Cromolyn?
The main goal of Cromolyn therapy in these patients was to taper





Twelve children with CIBD (7 with CUC and 5 with Crohn's) entered
a trial with Cromolyn Sodium. The patient groups consisted mostly of
those who had been treated with steroids over a 1-year period without
suppression of disease activity, and in whom steroids could not be tapered
without exacerbation. On commencement of Cromolyn therapy, steroid dos
ages ranged from 5-60 mg. q.d. (mean dose 30 mg. q.d.). Multiple com
plications of steroid therapy were observed in this group. Linear growth
retardation was exhibited by 5 patients, 2 with Crohn's and 3 with CUC.
One of the patients with CUC was also a Turner's mosaic. One patient
with Crohn's had severe osteoporosis with multiple vertebral collapse.
One Crohn's and 3 CUC patients were also Cushingoid. Severe side ef
fects of Azulfidine were noted in 4 patients, 3 of whom developed hemo
lytic anemia (1 Crohn's and 2 CUC), and 1 with CUC who developed total
body rash. Five others (2 Crohn's and 3 CUC) were currently taking Azul
fidine. Just prior to commencement of Cromolyn therapy, 2 patients (1
3 11
Crohn's and 1 CUC" ) developed severe exacerbation of the disease, re
quiring hospitalization for I.V. ACTH and blood transfusions. Three of
2 4 5
5 patients with Crohn's disease
' '
had undergone small and large bowel
resections, and all 3 showed recurrences of the disease at the site of
the anastomosis.
All patients with Crohn's disease had ileocolonic disease with
rectal involvement. Four of the 6 with ulcerative colitis had pancolonic
disease, and 1 had the disease confined to the rectum.
At the onset of
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the Cromolyn trial, ages ranged from 9 to 20 years, with a mean of 15
years. Sex distribution included 9 females (6 with CUC) and 3 males
(2 with Crohn's). All the patients in this study were white. Three pa
tients (2 with CUC and 1 Crohn's) had positive family histories of CIBD.
Cromolyn was given in the form of gelatin-coated capsules (20, 50,
100, 150 mg). Patients were instructed to open the capsules and dis
solve the contents in warm water. Cromolyn was to be taken 1 hour be
fore meals. Dosages varied from 300 to 600 mg daily, divided into 3 or
4 equal doses, according to each patient's convenience. At the time of
this writing, duration of the treatment varied from 6 to 18 months. Two
patients (1 male and 1 female who had Crohn's) did not respond to the
Cromolyn therapy after 3 and 1 month periods respectively, and under
went further surgery. Cromolyn was provided by Fisons Corporation, Ltd.,
Bedford, Mass. Previous drug therapy was continued for all patients
(Azulfidine for 5, oral steroids for 7, vitamin supplements, and anti-
diarrheal agents).
Before institution of Cromolyn therapy, the following laboratory
data were obtained to rule out any hematologic, renal or hepatic abnor
malities: CBC with differential, ESR, serum electrolytes, total protein
and albumin, creatinine, liver function tests and urinalysis. A complete
physical examination, including sigmoidoscopy and rectal suction biopsy,
was also performed.
Patients were seen in the Pediatric Gastroenterology Clinic appro




vals thereafter. Laboratory tests listed in the foregoing were repeated
during the monthly visits. Rectal suction biopsy was repeated approxi
mately 2 to 3 months following initiation of Cromolyn therapy.
METHODS OF ANALYSIS
A. Clinical Aspects
An index of disease activity was recorded for each patient both be
fore and following Cromolyn therapy. Patients were graded from I to V,
taking into account their overall sense of well being, the presence of
rectal bleeding, diarrhea, frequency and consistency of stools, and
whether steroids were being taken. Specific grading was as follows:
1. Symptom free, off steroids
2. Mild symptoms, off steroids. Occasional diarrhea, rare
episodes of blood in stool, normal laboratory data.
3. Mild symptoms, on steroids. Occasional diarrhea, rare
episodes of blood in stool, normal laboratory data.
4. Moderate symptoms, on steroids. More frequent diarrhea,
pain and bloody stools. Laboratory data (hematocrit,
estimated sedimentation rate, albumin) might be abnormal.
5. Severe symptoms, on steroids. Usually incapacitating;
requiring hospitalization.
This grading was determined by retrospective chart review.
B. Histological Aspects
Rectal mucosal biopsies were classified on the basis of their his
tological appearance before and following Cromolyn therapy as follows:
Stage 0: Essentially normal
Stage 1: Chronic inactive or healed
colitis (characterized by
focal areas of increased mucosal fibrosis, presence
of muciphages and distortion of normal crypt architec-
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ture with a slight to significant increase in infil
trate of; the lamina propria mostly mononuclear with
lymphocytes and plasma cells).
Stage 2: Chronic active colitis (characterized by a moderate
amount of infiltrate and the additional presence of
polymorphonuclears invading the superficial epithelium and
glands and sometimes forming crypt abscesses) .
All biopsy specimens were fixed in formalin and stained with Hema- -
toxylin-Eosin, Alcian Green and Masson's stain for routine histological
diagnosis. They were also stained with Toluidine Blue for its known
properties of enhancing the metachromasia of the mast cell granules,
showing them in shades ranging from blue to pink to violet tones.
' '
Histologic improvement during Cromolyn therapy was interpreted in
2 ways, either as a change in biopsy staging from chronic active colitis
(pre-Cromolyn) to chronic inactive colitis (post Cromolyn); or, if the
patient had inactive colitis by biopsy prior to treatment, as beneficial
if the biopsy following Cromolyn therapy did not show progression to
chronic active colitis. This was based on observations that mucosa of
patients with inflammatory bowel disease, even though in remission, will
always show signs of permanent damage, while the presence of acute changes





The number of granulated mast cells was then estimated in the
lamina propria of the rectal mucosal biopsies of children in this study
both before and after Cromolyn therapy. To be able to quantitate the




micrometer disc which was divided into 49 small squares, each 1.0 mm .
When used with an oil immersion lens (xlOO) and an xlO eyepiece, this
2
grid composed of the 49 smaller squares covered a field area of .01 mm .
To obtain this field area, the disc was calibrated against a stage micro
meter and a hemocytometer with subdivisions varying from .1 to .01 mm.
2
Another dies (A0-10 mm square divided into 100 smaller squares 1.0 mm )
was also calibrated in the same manner to confirm the previous results
when transformed mathematically to cover the same area as the Bausch &
2
Lomb disc. Therefore, to obtain a mast cell population 1 mm , at least
100 field areas, or 4900 small squares, had to be counted. This method
39
had previously been described in the literature by Lloyd et al.
Since the mast cell granules, if present, were not clearly identi
fied in areas covered by superficial or crypt epithelium, the squares
that fell on these epithelial components were not counted. Areas of
dense lymphoid aggregates, or invaded by abundant inflammatory infiltrate,
were more difficult to count, so efforts were concentrated on the less
dense areas of the lamina propria. Because of the small size of the
biopsies, and to avoid repetition of counts, an ordered sequence was fol
lowed, counting every other field area in more than 1 sectional cut of
the biopsy. A mean figure was calculated for each small square and this
2
number was then extrapolated to mast cells/mm in order to compare it
39
with previous studies. Results were then compared
with those found in
25 normal control specimens and 5 children with CUC and 5 with Crohn's
who were not treated with Cromolyn. The 25 control specimens of rectal
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mucosa were obtained from children with a recent change in bowel habits,
but who did not satisfy clinical criteria for inflammatory bowel disease.
They were similar in age and sex distribution to our study group. All
biopsies were treated identically and classified by the same histologic
criteria.
2
The mean number of granulated mast cells/mm was obtained for each
disease group (CUC vs Crohn's vs Controls) and the results were compared.
2
The values of mast cells/mm were then correlated with histologic grading
for each group as follows: Normal, Stage I CUC, Stage II CUC, Stage I
Crohn's, Stage II Crohn's. The mean number for each of these final sub
divisions was also compared and the results were analyzed statistically
58
using a One-way analysis of variance and comparison among class means.
An attempt was also made to correlate the grading of disease activity
with the mean number of mast cells within each class .
Finally, to determine whether Cromolyn has an effect on the rectal
mucosa similar to that on bronchial mucosa of asthmatics, the mean num
bers of granulated mast cells were calculated in our study group both be-
for and after Cromolyn therapy. Statistical comparisons were made using
a student's T-test for paired data.
This trial was not a double blind crossover, and control groups
were not chosen at random. Whether statistics should be used, therefore,
is a matter of much controversy, since in descriptive studies such as
this one might miss real findings by applying
tests which should not
have been used at all. Therefore, this study will attempt to analyse
the data with an open mind, concentrating more on the trends
of mast cells
29




Patient Group at Entrance into Study
Crohn's Disease
Pt.# Sex Age Age at Steroid Steroid Dose (mg) Disease Site of Previous Steroid Com*- Other
Onset Duration Start End Activity Disease Surgery plications Meds.
Start End




2 M 16 12 36 mos. 20 q o d 0 5 5 Ileo- Resection Growth retarda- Hyperal,
colonic ter. ileum tion Azulfi-
&-transv. dine
asc. colon
16 9 64 mos. 50 q d 20-10 q d 5 4 Ileo- Cushingoid Azulfi
dinecolonic
12 mos. 25 q d 0 4 2 Ileo-M 15 9 Distal Growth retarda- Hyperal,
colonic ileostomy tion Codeine
Subtotal
colectomy






Patient Group at Entrance into Study
Chronic Ulcerative Colitis
Pt.// Sex Age Age at Steroid Steroid Dose (mg) Disease Site of Previous Steroid Com-
Onset Duration Start End Activity Disease Surgery plications
Start End
6 F 9 6 22 mos. 30 q d 0
7 F 20 19 new pt.




9 F 19 7 108 mos. 15 q d 5-0 q d 4 3 Pan-
colonic
10 F 13 12 5 mos. 30-25 q d 25-10 q d 4 5 Pan-
colonic
11 F 12 11 12 mos. 30 q d 5-0 q d




























All 12 patients were symptomatic at the beginning of this study.
Only 1 patient (#7), who had ulcerative proctitis, had not been on sys
temic steroids before starting Cromolyn. The rationale for initiation of
Cromolyn therapy was her strong positive family and personal history of
allergies, as well as a clear component of food intolerance related to
the proctitis. (Table I)
Three of 5 patients with Crohn's disease (60%) improved clinically
in response to Cromolyn therapy. Two (40%) deteriorated and required
further surgery (ileo-ascending colectomy and total colectomy and ileos
tomy respectively) . Of the 3 patients who demonstrated clinical improve
ment, patient #4 was successfully tapered off steroids and remained
asymptomatic. Attempts at tapering steroids to 2.5 mg. q o d in the
2nd patient are proceeding slowly. Following initial diagnosis, the 3rd
patient never fully responded to steroid therapy. After 2 years on in
creasing doses of Prednisone, she presented with multiple vertebral col
lapse secondary to severe steroid osteoporosis. Steroids were discon
tinued at that point and she was begun on Cromolyn.
Six out of 7 children with CUC (85%) improved clinically. Only 1
patient (#10) never fully responded to steroids and could not be tapered.
She deteriorated clinically and underwent total colectomy and ileostomy.
In addition to her CIBD, she was Cushingoid, exhibited linear growth re
tardation (less than 3rd percentile in height), was a Turner's mosaic and
had chronic renal disease. Cromolyn provided temporary relief, however,
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and within 3 days after starting treatment, she passed her 1st formed
stool in 3 months. Initial attempts at tapering her steroids on alter
nate days were successful for 3 months, after which her disease exacer
bated. Steroids were subsequently increased to 30 mg. daily and further
attempts at tapering failed. She underwent surgery 7 months after the
Cromolyn therapy was begun.
Two of the 6 patients who demonstrated clinical improvement have
been successfully tapered off steroids. One, a 10 year old male, with
disease for 6 years, had, for the last 3 years, constantly been on ster
oids, except for a 4 month period in 1975. He exhibited growth retarda
tion. An exacerbation of symptoms was treated with Cromolyn. He has now
been on Cromolyn for 8 months, is asymptomatic and has grown 3 cm. The
other, a 9 year old female, had been on steroids for 22 months (except
for 3 weeks) since diagnosis was made. She was tapered, and has now been
on Cromolyn for 3 months, and completely off steroids. In 3 others,
the steroid dosage was lowered (30 to 7.5 mg., 45 to 20 mg., and 15 to
5 mg. daily) .
B. Histologic Grading of Rectal Biopsies
Before Cromolyn treatment, 4 out of 5 Crohn's patients had biopsies
consistent with chronic active colitis. One had healed or chronic in
active colitis histologically. Of 7 patients with CUC, 5 had active co
litis by biopsy, and 2 had healed inactive colitis. After Cromolyn
therapy, 2 of 4 children with Crohn's disease, initially classified as
active, were then classified as healed. The inflammatory process re
mained inactive in 1 patient. Biopsies from 2 of 5 children with CUC
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which initially showed active disease, became inactive or healed. On
the whole, none of the patients whose biopsies were classified as
chronic inactive" prior to Cromolyn therapy showed deterioration or
progression of the inflammatory process in the rectal mucosa following
Cromolyn therapy. (Fig. %)
C. Mast Cells
2
Mean values of granulated mast cells/mm in rectal lamina propria
are shown in Table II. No significant change was noted in the mast cell
population among these groups. A small increase in the number of mast
cells was noted in the control population over the children in the study
who had ulcerative colitis, and both these, in turn, were greater than
in children with Crohn's disease. These differences, however, were not
2
statistically significant. The mean numbers of mast cells/mm for each
histological class were correlated with histologic staging in inflamma
tory bowel disease. (Tables III-A, III-B)
The differences between all of these groups were tested using a
One-way analysis of variance with comparisons among class means, and
were not found to be statistically significant. However, after separating
these values by histologic grading, a very interesting pattern was ob
served. Mast cells were definitely increased in the healed, inactive
stage when compared to the chronic active stage, both in patients with
CUC and Crohn's disease.
Quantitative studies of mast cells were also done in rectal mucosal





Mean Value of Granulated Mast Cells/ram in Rectal Lamina Propria
Number of Number Mast S.E.of
Biopsies Cells/mm2 Mean
Controls 24 343 19
Ulcerative Colitis 19 328 + 21
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Mast Cell Correlation with Histologic
Staging in Inflammatory Bowel Disease
Crohn's Disease
Ulcerative Colitis
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and 6 with ulcerative colitis, the mean results for each group in mast
2
cells/mm , before and following Cromolyn therapy, were:
Pre Cromolyn Post Cromolyn
Chronic ulcerative colitis 272 (+ 43) 348 ( 20)
Crohn's disease 268 (+ 23) 305 (+ 16)
More detailed results are given in Table IV. Although granulated mast
cells increased after treatment, these values showed that the figures
were not statistically significant. Individually, not all patients ex
hibited an increase in mast cell population after Cromolyn treatment.
In those with Crohn's disease, 2 patients who showed an increase in mast
cells also had clinical and histologic improvement. These 2 showed an
2
increase of 123 mast cells/mm . In CUC patients, 4 who showed an in
crease in mast cells also had clinical and histologic improvement. Two
others who improved clinically, but had no histologic improvement in the
CUC either before or after Cromolyn treatment, showed a decrease in the
number of granulated mast cells.
The mean number of mast cells were calculated before and after Cro
molyn treatment in those patients who demonstrated histological and clin
ical improvement. The increase noted in those patients with CUC was
found to be statistically insignificant (p < .005), with a mean increase
? 2 2
of 132 mast cells/mm (from 240/mm to 372/mm ). The mean increase in
patients with Crohn's
disease who showed clinical and histologic improve-
2 2
ment was 125/mm (from 247/mm pre treatment to 3






Mean Values of Granulated Mast Cells/mm2 in Rectal
Lamina Propria Before and After Cromolyn Treatment
Crohn's Disease
Ulcerative Colitis













The mean number of mast cells/mm in patients prior to Cromolyn
therapy, who did not show combined histologic and clinical response to
the drug, was noticeably higher than the mean values of all patients in
that same group who were not part of this trial. The difference in mean
2
number of granulated mast cells/mm prior to Cromolyn therapy was even
more marked when comparing "responders" to "non-responders"- (Fig. 2,
Table V)
For the patients in this study group, mast cell counts in each rec
tal biopsy were also correlated with the index of disease activity for
each individual patient at the time the biopsy was obtained, in order to
ascertain if there was any gross difference or marked trend in the mast
cell populations of patients with severe disease vs those in milder
stages. Therefore, no distinction was made as to whether the biopsy was
taken before or after Cromolyn therapy. The results were as follows:








The difference in mast cell populations between any of these groups is
not that obvious, but a constant reciprocal pattern of decreasing numbers
of mast cells with increasing disease activity was observed.
Treatment with Cromolyn was not associated with any hepatic, hemato





Comparison of Mean Values of Mast Cells/mm in Lamina Propria of Pa
tients With CIBD Who Were Not Part of Study Groups, With "Responders"
and "Non-responders" to Cromolyn Before Initiating Cromolyn Therapy
All Patients "Responders" "Non-responders"
Controls 343 (25)
Crohn's Disease 304 (14) 247 (2) 426 (2)
Crohn's patients not
part of study group 297 (5)
Ulcerative Colitis 328 (19) 240 (4) 402 (2)
CUC not part of
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Fig. 2 Mean Numbers of Granulated Mast Cells/mm Before Cromolyn Treatment on Patients With
and Without




Mast cells have been implicated in the pathogenesis of ulcerative
colitis since 1957 when McGovern and Archer concluded that the reactions
observed in the bowel of these patients were typical of histamine-releas-
ing phenomenon. Through the analysis of 32 surgical and 20 autopsy spe
cimens, it was demonstrated that mast cells stained with Giemsa were
found in abundance in the human colonic submucosa and muscular coats.
This discovery was then initially linked to the psychologic hypothesis
for the etiology of CUC. Psychosomatic factors would hypothetically
cause the release of acetyl choline in the colon which, in turn, would
provoke the mast cells to degranulate and release histamine leading to
44
cbngestion, submucosal edema, muscle spasm and hypertrophy.
More detailed studies in this field followed, all suggesting that
mast cells were definitely increased in both colonic and rectal tissues




The literature is divided on the subject of Crohn's disease. Hiatt
and Katz were the first to report an increase in mast cells in the mus-
cularis and submucosa of the ileum of patients with regional enteritis
as opposed to controls.
These results were supported by Rao, who
found an increase in the number
of mast cells in the granulomas of
Crohn's disease by both light and electron-microscopic studies. A de
crease in the mast cell population of the rectum of patients with Crohn's
disease was noted by
Korelitz et^ al. , when comparing specimens of sig-
moidoscopic (-/or normal)
of Crohn's with those of sigmoidoscopic (-/or
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normal) CUC, but there was no decrease against a control population.
34
A -marked decrease in the number of mast cells in the lamina propria and
submucosa of the ileum, colon and rectum of biopsies involved by Crohn's
disease was reported by Lloyd when he compared these with normal and CUC
biopsies.
Results of this study suggest that there are no significant differ
ences in the granulated mast cell populations of patients with Crohn's
disease, CUC and the controls. When the biopsies are classified by their
2
histologic appearance, a smaller number of granulated mast cells/mm of
tissue are observed in the chronic active cases. This trend is seen
both in CUC and Crohn's patients.
Our observations seem to support the hypothesis that inflammation in
the bowel of patients with CIBD is secondary to a hypersensitivity re
action. In acute exacerbations in active CIBD caused by antigen-antibody
interactions (involving IgE or CF antibodies or immune complexes) , mast
cells would constantly degranulate releasing histamine, heparin and




Since our techniques identify only granulated mast cells
and not degranulated ones, we can only hypothesize that we are measuring
an increase in granulated mast cells rather than an increase in the ac
tual number of cells in the healed colitis group versus active colitis.
Ironically, other investigators who have reported an increase in intes
tinal mast cells vs a major histologic feature of CUC have indirectly
supported our results.
For example, McAuley and Sommers (1966) in the
first quantitative study of mast cells in colonic biopsies of patients
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with ulcerative colitis, noted that in 60% of their samples 0-5 out of
25) there were no mast cells present at all in the lamina propria. The
conclusion that mast cells were increased in CUC was based on the over
abundance of these cells counted in only 40% (10 out of 25) of the sam
ples when compared to all of the 25 controls. In explanation of these
results, they commented that mast cells are more often degranulated in
areas of acute inflammation, but curiously, all of their patients had
similarly active disease. Also, Bercowitz and Sommers, who were the
first to combine clinical and pathological criteria, claimed that through
different staining methods, they could identify both granulated and de
granulated mast cells in the submucosa, and found that 50% of the mast
cells were degranulated in active ulcerative colitis. They observed that,
in remission, submucosal granulated mast cells increased, and in relapse,
granulated mast cells decreased, while in the lamina propria the opposite
patterns occurred. No explanation was offered for the different trends
of mast cells in the separate intestinal layers. Eosinophils (30 x nl)
and plasma cells (15 x nl) were also markedly increased in the lamina
propria of patients with CUC.
34. 35
Korelitz and Sommers ,
'
in a study previously mentioned, noted an
increase in mast cell populations in patients with Crohn's disease and ul
cerative colitis who had normal (-) sigmoidoscopic examinations as com
pared to no significant
increase in patients with abnormal (+) sigmoido
scopic examinations. By comparison,
all patients in our study group had
abnormal (+) sigmoidoscopic examinations.
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In performing quantitative mast cell studies, we are aware that there
are multiple factors that could alter our counts, such as edema and areas
densely infiltrated by acute inflammatory cells. By being consistent in
our methods, we attempted to eliminate many of these variables that could
distort our results. Because of these inevitable variables, we have con
centrated our discussion on observed trends rather than concrete numbers.
39
The fact that our results differed from another similar recent study
could also be related indirectly to the fact that for the first time we
are dealing with a primarily pediatric population, both in our controls
and in our study group. Except for studies done in fetal rectal tissues
37
by Lindholm in 1959, we know of no other studies done in children.
Lindholm found no statistically significant differences among age groups,
but it has later been shown that post mortem specimens he used are really
not adequate for this type of quantitative investigation.
Our findings with Cromolyn therapy are more interesting.As a whole,
the clinical effects of Cromolyn were very beneficial. Six of 7 patients
with CUC (85%) improved clinically. An amelioration of their symptoms
was observed and efforts to reduce their steroid dosages were successful.
Steroids were successfully eliminated in only 2 of these. Three of 5 pa
tients with Crohn's disease (60%) showed signs of clinical improvement
with Cromolyn. Of these, 1
is now taking no steroids and remains asympto
matic.
How can we predict which patient with CIBD will respond to Cromolyn?
How is this patient different
from the non-responder? We attempted to
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answer these questions by pooling all our patients' data and grouping pa
tients by similar histologic, and clinical findings. In this fashion, we
found that
1. all of our patients with combined clinical and histological response
to Cromolyn showed an increase in the mast cell population of the lamina
propria after treatment. This group included 4 patients with CUC and 2
with Crohn's disease. The increase in patients with CUC was significant
(p<.005).
2. Two patients with CUC who demonstrated clinical but not histologic
improvement, did not show an increase in mast cells. In fact, both ex
hibited small decreases. These 2 patients had active disease histologic
ally 4 months after Cromolyn.
3. One patient who experienced clinical and histologic deterioration
during Cromolyn trial showed a decrease in mast cells.
4. All patients with histologic improvement also demonstrated clinical
response and an increase
in mast cells. This group, then, is identical
to category No. 1 above.
These observations suggest that histologic studies and quantitative
'
mast cell counts of rectal mucosa in combination
are probably the best
criteria to determine which patient will show a better response to Cro
molyn therapy.
Favorable response to Cromolyn was previously seen in patients with
CUC and proctitis, but changes





All of these patients were
ff steroids and in remission
at the onset of the study. A follow-up re-
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port on the patients with CUC on Cromolyn (DSCG) reyealed a significant
reduction in chronic inflammatory cellular infiltration. Quantitative
counts confirmed a decrease in polys, plasma cells and lymphocytes, but
most significantly in eosinophil counts. Immunofluorescent studies in
this same group did not show any change in the immunoglobulins during
40
Cromolyn therapy.
It is of interest that Heatley had previously observed that patients
with proctitis who showed better response to Cromolyn, had increased num
bers of eosinophils in rectal biopsies prior to therapy. Unfortunately,
we have no follow-up study on this group, but if we associate this obser
vation of increased eosinophils in the responders with Mani's findings
that Cromolyn significantly decreases the number of eosinophils, it is
questionable whether Cromolyn is also inhibiting the release of ECF-A
from tissue involved in allergic reactions of the colon. Eosinophils,
like mast cells, have long been associated in sites of antigen-antibody
reactions such as nasal and bronchial mucosa of atopic individuals.
They were also found to be the most notably increased connective tissue
cells in CUC. Yet the role of the eosinophil is not clear, nor is its
relationship to the mast cell. In vitro it has been shown that the eo
sinophil can phagocytize antigen-antibody complexes, and by degranulating




in eosinophil infiltration in active disease when
mast cells decrease presumably because
of degranulation.
Because of our findings, we disagree with others who believe that
Cromolyn must
act differently on the gastrointestinal tract. The de-
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crease in eosinophils and the other ant i- inflammatory effects in the in
testinal mucosa following Cromolyn therapy noted by Mani and Heatley
correlate with the known mode of action of Cromolyn. Since it is thought
to prevent degranulation of mast cells following certain antigen-antibody
reactions (mainly Type I, IgE - allergic, and Type III
- Arthus or im
mune complex) .
'
the end result might be a decreased amount of hista
mine in the tissue. If eosinophils are attracted to allergic tissue sites
because of the high histamine content, a drop in the number of eosinophils
following Cromolyn therapy could easily be understood.
Cromolyn does not prevent the fixation of Ig (immunoglobulin) to the
mast cell membrane. Yet, conflicting studies with contradictory results
on IgE levels in the mucosa of patients with CIBD all arrive at the same
... . . . , J 25,40
conclusion, i.e., a Type I hypersensitivity reaction is involved.
These include a report of an increase in IgE in biopsy tissue from pa
tients with proctitis and a decrease of IgE in patients with Crohn's
4 20
disease. Increased levels of IgG have been reported by Auiti, Gebbers,
25 33
and Heatley. Decreased levels of IgA have been
noted by Gelzayd, and
Gebbers,20 and increased IgA levels by Auiti. Recently C was demon
strated at the basement membrane
of surface epithelial cells of the colon
20
in acute relapses of ulcerative colitis,
a finding that strongly links
CIBD with the immune complex type
of disease. No matter which immune
mechanism is responsible
for the exacerbations of CIBD (? immediate vs
? immune complex or Arthus),
the mast cell, with its pharmacologic media-
inside its cytoplasmic granules,





Mast cells are known to he tissue receptors for IgE antibodies (f 1
and are degranulated during Type I hypersensitivity reactions. Circula
ting immune complexes which fix complement generage a Cj. fragment (chemo-
feactic, anaphylatoxic) which also stimulates degranulation of the mast
cell. Finally, effector T-cells in delayed hypersensitivity reactions
could possibly indirectly induce mast cells in neighboring regions to de-
granulate. Recent evidence suggests that a type of mast cell in the
rat is thought to be a postmitotic derivative of the T-cell system, as
the plasma cell is a postmitotic B-cell derivative. If this is finally
proven true in humans, the mast cell possibly would be more directly in
volved in cell-mediated reactions of the bowel.
The possibility that mast cells are involved in more than one way
in spreading the inflammation of the bowel in patients with CIBD is sug
gested by our results. A marked increase in the number of granulated
2
mast cells/mm prior to Cromolyn therapy was noted in those patients who
did not show a combined clinical and histological response to Cromolyn
(i.e., "non-responders"). This isolated finding (Table V) seems to con
tradict our other observations that the more active the disease, the
smaller number of granulated mast cells. Particularly this is so since
all non-responders were in Stage 4 or 5 of disease activity, all were
on steroids, and all had
active disease histologically. Therefore, the
non-responders seem to fall
into a category of their own. Results sug
gest that either (1)
mucosal inflammation is precipitated by a different
mechanism in which
the mast cell is not directly involved and therefore
Cromolyn is not effective,
or (2) mucosal inflammation is secondary to
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an overabundance of granulated and degranulated mast cells refractory to
Cromolyn therapy.
It can be implied that two processes may coexist in CIBD. In the
patient who responds to Cromolyn, an allergic component or circulating im
mune complexes or Arthus type of reactions play an important role in the
pathogenesis of the disease, and these antigen-antibody interactions
would, in turn, be constantly degranulating the mast cells. In the non-
responders, presumably either a cell-mediated immune process or other un
known mechanisms would be the primary activators of these diseases, and
mast cells would only be degranulated as a secondary non-specific com
ponent .
CONCLUSION
After a detailed quantitative analysis of the granulated mast cell
populations of the rectal biopsies in this study, we have been able to
2
establish standard values of mast cells/mm in the lamina propria for
(a) normal controls in a pediatric population, and (b) children with
Crohn's disease and CUC in both active and inactive histologic stages
of these diseases.
We have also studied the clinical and histological effects of Cro
molyn on CIBD. Cromolyn
Sodium seems to be a logical alternative in the
therapy of children
with inflammatory bowel disease. Since the natural
history of this disease
is so unpredictable, we still cannot be sure of
the exact role
of Cromolyn in long-term management of these patients. The
eaning of our promising findings
is thus limited by the short duration
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of this trial. For the child who has not had significant improvement on
steroids or Azulfidine alone, and who exhibits complications of steroid
therapy, Cromolyn certainly is of value. Future studies might still show
this drug to be helpful in newly diagnosed patients. Because the pa
tients who responded most favorably to Cromolyn, both by clinical and
histological criteria, had the lowest pre-treatment mast cell levels and
showed an increase in the mast cell population, we believe that the bene
ficial effects of Cromolyn may be directly related to its known action
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